Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, comments on the changing treatment landscape of Hodgkin lymphoma (HL), highlighting the value of de-escalating treatment intensity and implementing individualized response-adaptive approaches that maintain high efficacy. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved